VF
DNLI icon

Virtu Financial’s Denali Therapeutics DNLI Stock Holding History

Virtu Financial’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,362
Closed -$833K – 1754
2026
Q1 		$833K Buy
+43,362
New +$863K 0.03% 373
2025
Q3 		– Sell
-18,438
Closed -$258K – 1594
2025
Q2 		$258K Buy
+18,438
New +$260K 0.01% 814
2024
Q1 		– Sell
-15,576
Closed -$334K – 1553
2023
Q4 		$334K Buy
+15,576
New +$308K 0.03% 563
2021
Q1 		– Sell
-3,373
Closed -$283K – 1688
2020
Q4 		$283K Sell
3,373
-4,428
-57% -$268K 0.03% 667
2020
Q3 		$280K Buy
+7,801
New +$235K 0.05% 462
2019
Q4 		– Sell
-10,614
Closed -$163K – 1517
2019
Q3 		$163K Buy
+10,614
New +$203K 0.01% 1010
2018
Q3 		– Sell
-12,274
Closed -$187K – 1661
2018
Q2 		$187K Buy
+12,274
New +$231K 0.01% 1531

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial's DNLI Position: Q2 2026 in Review

Virtu Financial sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 43,362 shares — an estimated $833K sold.

Virtu Financial first reported a position in DNLI in Q2 2018 and held it in 7 quarters. The position peaked at $833K in Q1 2026. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Virtu Financial reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 43,362 Denali Therapeutics shares in Q2 2026, an estimated $833K.
  • Virtu Financial first reported a position in Denali Therapeutics in Q2 2018 and held it in 7 quarters.
  • Virtu Financial's Denali Therapeutics position peaked at $833K in Q1 2026.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.